Viatris Asks Fed. Circ. To Revive Hypertension Drug IP Fight

Pharmaceutical giant Viatris has urged the Federal Circuit to reverse a lower court decision blocking its planned generic in rival Actelion's patent suit over blood pressure treatment Veletri, contending that a...

Already a subscriber? Click here to view full article